DSXi is upgradable to dual-head configurationNuclear medicine vendor SMV America plans to showcase a new single-head gamma camera that is upgradable to a dual-head variable-angle model at the upcoming Society of Nuclear Medicine meeting in
DSXi is upgradable to dual-head configuration
Nuclear medicine vendor SMV America plans to showcase a new single-head gamma camera that is upgradable to a dual-head variable-angle model at the upcoming Society of Nuclear Medicine meeting in Toronto. SMVs DSXi camera broadens the companys product line and makes its single-head offerings more competitive, according to Bill Bishop, vice president of business development for the Twinsburg, OH-based company.
SMV was formed in 1995 through the merger of gamma camera vendors Summit Nuclear and Sopha Medical (SCAN 6/21/95). Summit was prominent in digital gamma camera technology, while at the time of the merger Sopha was one of the few nuclear medicine vendors to offer a variable-angle dual-head gamma camera. The new company suffered a few turbulent initial years, but now appears to be back on track: In the month of December, SMV set a company record with more than $8 million in U.S. sales.
DSXi is designed to make SMV more competitive in the single-head segment, and the system began shipping this month. It carries the same detector as the variable-angle DST-XL, as well as the same open-gantry configuration and long-access SPECT capability, which saves imaging time during oncology applications.
SMV acknowledges that the single-head segment is shrinking, and now represents only 25% of the total market for gamma cameras. But DSXis upgradability will appeal to those hospitals that dont want to spring for a dual-head right away, but would like to have the option to do so in the future. DSXis price depends on configuration but remains comparable to previous single-head models in SMVs product line, Bishop said.
SMV will also present its Transmission Attenuation Correction (TAC) technology at the SNM meeting as part of a package that includes the vendors Stasis motion correction algorithm and Restore depth-dependent resolution recovery and scatter reduction technique. After four years of development, SMV began shipping the package in April for SPECT and gated SPECT studies, using both thallium and technetium. Company executives believe that SMVs measured approach to the technology will help it avoid problems other companies have encountered.
The best analogy to describe our TAC program is the tortoise and the hare, said Lonnie Mixon, vice president of clinical marketing. There were several companies that early on jumped out of the gate, throwing on transmission sources and creating transmission maps, starting to scale up internal structures, with very little regard for preliminary image preparation. We have refined and sharpened the image as much as possible.
Finally, SMV will display images from its Volumetric Coincidence Reconstruction (VCR) program, highlighting the programs use of Fourier rebinning (FORE) and ordered subset expectation maximization (OSEM), iterative reconstruction algorithms used to interpret data. The company will feature what it calls PET-equivalent corrections, including randoms correction, as part of its VCR package. SMV will also present new 332-MHz IBM RS/6000 workstations, as well as DICOM software and IBMs continuous voice recognition program, MedSpeak, Bishop said.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.